This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Baird, D. D. Articles by Dunson, D. B. Search for Related Content PubMed PubMed Citation Articles by Baird, D. D. Articles by Kesner, J. S. Articles by Dunson, D. B. Social Bookmarking                   What's this?

Luteinizing Hormone in Premenopausal Women May Stimulate Uterine Leiomyomata Development

Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina; Biomonitoring and Health Assessment Branch, Division of Applied Research and Technology, National Institutes of Occupational Safety and Health, Cincinnati, Ohio; Biostatistics Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina; baird{at}niehs.nih.gov

James S. Kesner, PhD

David B. Dunson, PhD

Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina; Biomonitoring and Health Assessment Branch, Division of Applied Research and Technology, National Institutes of Occupational Safety and Health, Cincinnati, Ohio; Biostatistics Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina

Objective: Human chorionic gonadotropin (hCG) has proliferative effects on uterine smooth muscle and leiomyoma tissue in vitro. We hypothesized that luteinizing hormone (LH) would have the same effect by activating the LH/hCG receptor, and it would follow that premenopausal women with higher LH levels would be more likely to have leiomyomata.

Methods: Randomly selected women, aged 35 to 49 years, from a prepaid health plan were screened for leiomyomata with pelvic ultrasound. Urine samples collected during the first or last 5 days of the menstrual cycle were analyzed for LH by immunoflueorometric assay, and concentrations were corrected for creatinine (n = 523). Logistic regression and Bayes analyses were used to evaluate the association of LH with presence and size of leiomyomata, adjusting for age, and other risk factors.

Results: Women with higher LH were more likely to have leiomyomata (adjusted odds ratios for second and third tertiles were 1.7 and 2.0 compared with lower tertile; 95% confidence intervals, 1.0 to 2.7 and 1.2 to 3.4, respectively). The association was stronger for large leiomyomata. Bayes analyses designed to estimate LH effects on tumor onset separately from tumor showed significantly accelerated tumor growth showed significantly accelerated tumor onset but little evidence of effects on tumor growth. Age, an independent risk factor for leiomyomata, was not affected by inclusion of LH in the logistic models.

Conclusions: As hypothesized, women with higher LH were more likely to have leiomyomata, but this did not explain the age-related increase in leiomyomata during perimenopausal ages. Determining whether LH is causal or a marker for susceptibility will require further research.

Key Words: Uterine leiomyoma • uterine fibroids • luteinizing hromone • perimenopause

Journal of the Society for Gynecologic Investigation, Vol. 13, No. 2, 130-135 (2006)
DOI: 10.1016/j.jsgi.2005.12.001


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?